nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—DRD5—attention deficit hyperactivity disorder	0.153	0.199	CbGaD
Aripiprazole—ADRA2C—attention deficit hyperactivity disorder	0.145	0.187	CbGaD
Aripiprazole—DRD4—attention deficit hyperactivity disorder	0.0785	0.102	CbGaD
Aripiprazole—HTR1B—attention deficit hyperactivity disorder	0.0697	0.0903	CbGaD
Aripiprazole—DRD3—attention deficit hyperactivity disorder	0.0677	0.0876	CbGaD
Aripiprazole—DRD1—attention deficit hyperactivity disorder	0.0664	0.086	CbGaD
Aripiprazole—ADRA2A—attention deficit hyperactivity disorder	0.0617	0.0799	CbGaD
Aripiprazole—SLC6A4—attention deficit hyperactivity disorder	0.0471	0.061	CbGaD
Aripiprazole—DRD2—attention deficit hyperactivity disorder	0.0468	0.0606	CbGaD
Aripiprazole—HTR2A—attention deficit hyperactivity disorder	0.0362	0.0469	CbGaD
Aripiprazole—HTR7—locus ceruleus—attention deficit hyperactivity disorder	0.00362	0.0585	CbGeAlD
Aripiprazole—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00226	0.0365	CbGeAlD
Aripiprazole—HTR7—autonomic nervous system—attention deficit hyperactivity disorder	0.00192	0.0311	CbGeAlD
Aripiprazole—HTR1E—forebrain—attention deficit hyperactivity disorder	0.00123	0.0199	CbGeAlD
Aripiprazole—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.0012	0.0194	CbGeAlD
Aripiprazole—HTR6—forebrain—attention deficit hyperactivity disorder	0.000964	0.0156	CbGeAlD
Aripiprazole—DRD5—forebrain—attention deficit hyperactivity disorder	0.000939	0.0152	CbGeAlD
Aripiprazole—H1F0—forebrain—attention deficit hyperactivity disorder	0.000726	0.0117	CbGeAlD
Aripiprazole—DRD1—forebrain—attention deficit hyperactivity disorder	0.000717	0.0116	CbGeAlD
Aripiprazole—HTR3A—forebrain—attention deficit hyperactivity disorder	0.000693	0.0112	CbGeAlD
Aripiprazole—HTR1E—nervous system—attention deficit hyperactivity disorder	0.000667	0.0108	CbGeAlD
Aripiprazole—HTR1E—central nervous system—attention deficit hyperactivity disorder	0.000642	0.0104	CbGeAlD
Aripiprazole—Ziprasidone—DRD5—attention deficit hyperactivity disorder	0.000626	0.103	CrCbGaD
Aripiprazole—H1F0—cardiovascular system—attention deficit hyperactivity disorder	0.000614	0.00993	CbGeAlD
Aripiprazole—DRD4—brain—attention deficit hyperactivity disorder	0.000591	0.00956	CbGeAlD
Aripiprazole—Ziprasidone—ADRA2C—attention deficit hyperactivity disorder	0.00059	0.0969	CrCbGaD
Aripiprazole—CHRM4—nervous system—attention deficit hyperactivity disorder	0.000585	0.00945	CbGeAlD
Aripiprazole—HTR1B—forebrain—attention deficit hyperactivity disorder	0.000581	0.00939	CbGeAlD
Aripiprazole—CHRM2—forebrain—attention deficit hyperactivity disorder	0.000578	0.00934	CbGeAlD
Aripiprazole—CHRM4—central nervous system—attention deficit hyperactivity disorder	0.000563	0.0091	CbGeAlD
Aripiprazole—HTR1D—forebrain—attention deficit hyperactivity disorder	0.000563	0.00909	CbGeAlD
Aripiprazole—HTR2C—forebrain—attention deficit hyperactivity disorder	0.000557	0.009	CbGeAlD
Aripiprazole—ADRB1—forebrain—attention deficit hyperactivity disorder	0.000547	0.00884	CbGeAlD
Aripiprazole—DRD3—nervous system—attention deficit hyperactivity disorder	0.000544	0.00879	CbGeAlD
Aripiprazole—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.000528	0.00854	CbGeAlD
Aripiprazole—CHRM1—forebrain—attention deficit hyperactivity disorder	0.000526	0.0085	CbGeAlD
Aripiprazole—DRD3—central nervous system—attention deficit hyperactivity disorder	0.000524	0.00846	CbGeAlD
Aripiprazole—HTR6—nervous system—attention deficit hyperactivity disorder	0.000523	0.00846	CbGeAlD
Aripiprazole—HTR2B—forebrain—attention deficit hyperactivity disorder	0.000523	0.00846	CbGeAlD
Aripiprazole—HTR1E—brain—attention deficit hyperactivity disorder	0.00051	0.00824	CbGeAlD
Aripiprazole—DRD5—nervous system—attention deficit hyperactivity disorder	0.00051	0.00824	CbGeAlD
Aripiprazole—Vilazodone—SLC6A4—attention deficit hyperactivity disorder	0.000507	0.0833	CrCbGaD
Aripiprazole—Vilazodone—DRD2—attention deficit hyperactivity disorder	0.000505	0.0828	CrCbGaD
Aripiprazole—HTR6—central nervous system—attention deficit hyperactivity disorder	0.000504	0.00814	CbGeAlD
Aripiprazole—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.000491	0.00794	CbGeAlD
Aripiprazole—DRD5—central nervous system—attention deficit hyperactivity disorder	0.000491	0.00793	CbGeAlD
Aripiprazole—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.000489	0.0079	CbGeAlD
Aripiprazole—H1F0—midbrain—attention deficit hyperactivity disorder	0.00048	0.00775	CbGeAlD
Aripiprazole—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.000476	0.00769	CbGeAlD
Aripiprazole—DRD1—midbrain—attention deficit hyperactivity disorder	0.000474	0.00765	CbGeAlD
Aripiprazole—CHRM3—forebrain—attention deficit hyperactivity disorder	0.000471	0.00761	CbGeAlD
Aripiprazole—HTR1A—forebrain—attention deficit hyperactivity disorder	0.000469	0.00758	CbGeAlD
Aripiprazole—ADRB1—cardiovascular system—attention deficit hyperactivity disorder	0.000462	0.00747	CbGeAlD
Aripiprazole—CHRM5—nervous system—attention deficit hyperactivity disorder	0.000457	0.00739	CbGeAlD
Aripiprazole—HTR7—forebrain—attention deficit hyperactivity disorder	0.000448	0.00724	CbGeAlD
Aripiprazole—CHRM4—brain—attention deficit hyperactivity disorder	0.000447	0.00723	CbGeAlD
Aripiprazole—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.000445	0.00719	CbGeAlD
Aripiprazole—HTR2B—cardiovascular system—attention deficit hyperactivity disorder	0.000443	0.00715	CbGeAlD
Aripiprazole—CHRM5—central nervous system—attention deficit hyperactivity disorder	0.00044	0.00711	CbGeAlD
Aripiprazole—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000432	0.00699	CbGeAlD
Aripiprazole—DRD2—forebrain—attention deficit hyperactivity disorder	0.000424	0.00685	CbGeAlD
Aripiprazole—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000418	0.00675	CbGeAlD
Aripiprazole—KCNH2—forebrain—attention deficit hyperactivity disorder	0.000418	0.00675	CbGeAlD
Aripiprazole—DRD3—brain—attention deficit hyperactivity disorder	0.000416	0.00672	CbGeAlD
Aripiprazole—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000402	0.0065	CbGeAlD
Aripiprazole—HTR6—brain—attention deficit hyperactivity disorder	0.0004	0.00647	CbGeAlD
Aripiprazole—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.000397	0.00641	CbGeAlD
Aripiprazole—H1F0—nervous system—attention deficit hyperactivity disorder	0.000394	0.00637	CbGeAlD
Aripiprazole—DRD5—brain—attention deficit hyperactivity disorder	0.00039	0.00629	CbGeAlD
Aripiprazole—DRD1—nervous system—attention deficit hyperactivity disorder	0.000389	0.00629	CbGeAlD
Aripiprazole—HTR1B—midbrain—attention deficit hyperactivity disorder	0.000384	0.0062	CbGeAlD
Aripiprazole—H1F0—central nervous system—attention deficit hyperactivity disorder	0.00038	0.00614	CbGeAlD
Aripiprazole—HTR7—cardiovascular system—attention deficit hyperactivity disorder	0.000379	0.00612	CbGeAlD
Aripiprazole—HTR3A—nervous system—attention deficit hyperactivity disorder	0.000376	0.00608	CbGeAlD
Aripiprazole—DRD1—central nervous system—attention deficit hyperactivity disorder	0.000375	0.00606	CbGeAlD
Aripiprazole—HTR1D—midbrain—attention deficit hyperactivity disorder	0.000372	0.006	CbGeAlD
Aripiprazole—H1F0—cerebellum—attention deficit hyperactivity disorder	0.000371	0.006	CbGeAlD
Aripiprazole—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000368	0.00595	CbGeAlD
Aripiprazole—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000366	0.00591	CbGeAlD
Aripiprazole—HTR3A—central nervous system—attention deficit hyperactivity disorder	0.000362	0.00585	CbGeAlD
Aripiprazole—KCNH2—cardiovascular system—attention deficit hyperactivity disorder	0.000353	0.00571	CbGeAlD
Aripiprazole—CHRM5—brain—attention deficit hyperactivity disorder	0.000349	0.00565	CbGeAlD
Aripiprazole—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.000349	0.00564	CbGeAlD
Aripiprazole—HRH1—forebrain—attention deficit hyperactivity disorder	0.000335	0.00541	CbGeAlD
Aripiprazole—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000329	0.00531	CbGeAlD
Aripiprazole—Ziprasidone—DRD4—attention deficit hyperactivity disorder	0.00032	0.0526	CrCbGaD
Aripiprazole—ADRA1B—brain—attention deficit hyperactivity disorder	0.000319	0.00516	CbGeAlD
Aripiprazole—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000316	0.0051	CbGeAlD
Aripiprazole—CHRM2—nervous system—attention deficit hyperactivity disorder	0.000314	0.00507	CbGeAlD
Aripiprazole—HTR1A—midbrain—attention deficit hyperactivity disorder	0.00031	0.00501	CbGeAlD
Aripiprazole—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000305	0.00494	CbGeAlD
Aripiprazole—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000304	0.00491	CbGeAlD
Aripiprazole—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000303	0.00489	CbGeAlD
Aripiprazole—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.000302	0.00488	CbGeAlD
Aripiprazole—H1F0—brain—attention deficit hyperactivity disorder	0.000301	0.00487	CbGeAlD
Aripiprazole—DRD1—brain—attention deficit hyperactivity disorder	0.000298	0.00481	CbGeAlD
Aripiprazole—ADRB1—nervous system—attention deficit hyperactivity disorder	0.000297	0.0048	CbGeAlD
Aripiprazole—HTR7—midbrain—attention deficit hyperactivity disorder	0.000296	0.00478	CbGeAlD
Aripiprazole—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000294	0.00475	CbGeAlD
Aripiprazole—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000291	0.00471	CbGeAlD
Aripiprazole—HTR3A—brain—attention deficit hyperactivity disorder	0.000287	0.00465	CbGeAlD
Aripiprazole—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.000287	0.00463	CbGeAlD
Aripiprazole—ADRB1—central nervous system—attention deficit hyperactivity disorder	0.000286	0.00462	CbGeAlD
Aripiprazole—CHRM1—nervous system—attention deficit hyperactivity disorder	0.000286	0.00462	CbGeAlD
Aripiprazole—Ziprasidone—HTR1B—attention deficit hyperactivity disorder	0.000284	0.0467	CrCbGaD
Aripiprazole—HTR2B—nervous system—attention deficit hyperactivity disorder	0.000284	0.00459	CbGeAlD
Aripiprazole—DRD2—midbrain—attention deficit hyperactivity disorder	0.00028	0.00452	CbGeAlD
Aripiprazole—HTR2A—forebrain—attention deficit hyperactivity disorder	0.00028	0.00452	CbGeAlD
Aripiprazole—Ziprasidone—DRD3—attention deficit hyperactivity disorder	0.000276	0.0453	CrCbGaD
Aripiprazole—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.000276	0.00446	CbGeAlD
Aripiprazole—KCNH2—midbrain—attention deficit hyperactivity disorder	0.000276	0.00446	CbGeAlD
Aripiprazole—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.000275	0.00444	CbGeAlD
Aripiprazole—HTR2B—central nervous system—attention deficit hyperactivity disorder	0.000274	0.00442	CbGeAlD
Aripiprazole—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000272	0.0044	CbGeAlD
Aripiprazole—Ziprasidone—DRD1—attention deficit hyperactivity disorder	0.000271	0.0445	CrCbGaD
Aripiprazole—CHRM3—nervous system—attention deficit hyperactivity disorder	0.000256	0.00413	CbGeAlD
Aripiprazole—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000255	0.00411	CbGeAlD
Aripiprazole—HTR1A—nervous system—attention deficit hyperactivity disorder	0.000255	0.00411	CbGeAlD
Aripiprazole—Ziprasidone—ADRA2A—attention deficit hyperactivity disorder	0.000252	0.0413	CrCbGaD
Aripiprazole—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.000246	0.00398	CbGeAlD
Aripiprazole—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000245	0.00396	CbGeAlD
Aripiprazole—HTR7—nervous system—attention deficit hyperactivity disorder	0.000243	0.00393	CbGeAlD
Aripiprazole—HTR1B—brain—attention deficit hyperactivity disorder	0.000241	0.0039	CbGeAlD
Aripiprazole—CHRM2—brain—attention deficit hyperactivity disorder	0.00024	0.00388	CbGeAlD
Aripiprazole—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.00024	0.00387	CbGeAlD
Aripiprazole—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000236	0.00382	CbGeAlD
Aripiprazole—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000235	0.00379	CbGeAlD
Aripiprazole—HTR7—central nervous system—attention deficit hyperactivity disorder	0.000234	0.00379	CbGeAlD
Aripiprazole—HTR1D—brain—attention deficit hyperactivity disorder	0.000233	0.00377	CbGeAlD
Aripiprazole—HTR2C—brain—attention deficit hyperactivity disorder	0.000231	0.00374	CbGeAlD
Aripiprazole—DRD2—nervous system—attention deficit hyperactivity disorder	0.00023	0.00372	CbGeAlD
Aripiprazole—HTR7—cerebellum—attention deficit hyperactivity disorder	0.000229	0.0037	CbGeAlD
Aripiprazole—ADRB1—brain—attention deficit hyperactivity disorder	0.000227	0.00367	CbGeAlD
Aripiprazole—KCNH2—nervous system—attention deficit hyperactivity disorder	0.000227	0.00366	CbGeAlD
Aripiprazole—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000226	0.00365	CbGeAlD
Aripiprazole—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.000224	0.00361	CbGeAlD
Aripiprazole—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000222	0.00358	CbGeAlD
Aripiprazole—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000221	0.00357	CbGeAlD
Aripiprazole—SLC6A4—brain—attention deficit hyperactivity disorder	0.000219	0.00354	CbGeAlD
Aripiprazole—CHRM1—brain—attention deficit hyperactivity disorder	0.000218	0.00353	CbGeAlD
Aripiprazole—KCNH2—central nervous system—attention deficit hyperactivity disorder	0.000218	0.00353	CbGeAlD
Aripiprazole—HTR2B—brain—attention deficit hyperactivity disorder	0.000217	0.00351	CbGeAlD
Aripiprazole—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000217	0.00351	CbGeAlD
Aripiprazole—DRD2—cerebellum—attention deficit hyperactivity disorder	0.000217	0.0035	CbGeAlD
Aripiprazole—Nefazodone—SLC6A3—attention deficit hyperactivity disorder	0.000216	0.0355	CrCbGaD
Aripiprazole—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000215	0.00348	CbGeAlD
Aripiprazole—KCNH2—cerebellum—attention deficit hyperactivity disorder	0.000213	0.00345	CbGeAlD
Aripiprazole—Nefazodone—ADRA2A—attention deficit hyperactivity disorder	0.000212	0.0348	CrCbGaD
Aripiprazole—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.00021	0.0034	CbGeAlD
Aripiprazole—Trazodone—ADRA2A—attention deficit hyperactivity disorder	0.000196	0.0322	CrCbGaD
Aripiprazole—CHRM3—brain—attention deficit hyperactivity disorder	0.000195	0.00316	CbGeAlD
Aripiprazole—HTR1A—brain—attention deficit hyperactivity disorder	0.000195	0.00314	CbGeAlD
Aripiprazole—Prochlorperazine—DRD3—attention deficit hyperactivity disorder	0.000192	0.0316	CrCbGaD
Aripiprazole—Ziprasidone—SLC6A4—attention deficit hyperactivity disorder	0.000192	0.0315	CrCbGaD
Aripiprazole—Ziprasidone—DRD2—attention deficit hyperactivity disorder	0.000191	0.0314	CrCbGaD
Aripiprazole—HTR7—brain—attention deficit hyperactivity disorder	0.000186	0.00301	CbGeAlD
Aripiprazole—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000185	0.00298	CbGeAlD
Aripiprazole—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000183	0.00296	CbGeAlD
Aripiprazole—HRH1—nervous system—attention deficit hyperactivity disorder	0.000182	0.00294	CbGeAlD
Aripiprazole—ADRA1A—brain—attention deficit hyperactivity disorder	0.000179	0.0029	CbGeAlD
Aripiprazole—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000178	0.00288	CbGeAlD
Aripiprazole—DRD2—brain—attention deficit hyperactivity disorder	0.000176	0.00284	CbGeAlD
Aripiprazole—HRH1—central nervous system—attention deficit hyperactivity disorder	0.000175	0.00283	CbGeAlD
Aripiprazole—KCNH2—brain—attention deficit hyperactivity disorder	0.000173	0.0028	CbGeAlD
Aripiprazole—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000172	0.00278	CbGeAlD
Aripiprazole—ADRA2C—brain—attention deficit hyperactivity disorder	0.000171	0.00276	CbGeAlD
Aripiprazole—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000168	0.00271	CbGeAlD
Aripiprazole—Nefazodone—SLC6A4—attention deficit hyperactivity disorder	0.000162	0.0265	CrCbGaD
Aripiprazole—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000155	0.0025	CbGeAlD
Aripiprazole—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000152	0.00245	CbGeAlD
Aripiprazole—Trazodone—SLC6A4—attention deficit hyperactivity disorder	0.000149	0.0245	CrCbGaD
Aripiprazole—Ziprasidone—HTR2A—attention deficit hyperactivity disorder	0.000148	0.0242	CrCbGaD
Aripiprazole—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000146	0.00236	CbGeAlD
Aripiprazole—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000143	0.00231	CbGeAlD
Aripiprazole—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00014	0.00227	CbGeAlD
Aripiprazole—HRH1—brain—attention deficit hyperactivity disorder	0.000139	0.00224	CbGeAlD
Aripiprazole—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000138	0.00223	CbGeAlD
Aripiprazole—ADRA2A—brain—attention deficit hyperactivity disorder	0.000136	0.0022	CbGeAlD
Aripiprazole—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000135	0.00219	CbGeAlD
Aripiprazole—Perphenazine—DRD1—attention deficit hyperactivity disorder	0.000135	0.0222	CrCbGaD
Aripiprazole—Prochlorperazine—DRD2—attention deficit hyperactivity disorder	0.000133	0.0218	CrCbGaD
Aripiprazole—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000133	0.00215	CbGeAlD
Aripiprazole—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.00013	0.0021	CbGeAlD
Aripiprazole—Perphenazine—ADRA2A—attention deficit hyperactivity disorder	0.000125	0.0206	CrCbGaD
Aripiprazole—Nefazodone—HTR2A—attention deficit hyperactivity disorder	0.000124	0.0204	CrCbGaD
Aripiprazole—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000121	0.00195	CbGeAlD
Aripiprazole—HTR2A—brain—attention deficit hyperactivity disorder	0.000116	0.00187	CbGeAlD
Aripiprazole—Trazodone—HTR2A—attention deficit hyperactivity disorder	0.000115	0.0189	CrCbGaD
Aripiprazole—CYP2D6—brain—attention deficit hyperactivity disorder	0.000106	0.00171	CbGeAlD
Aripiprazole—ABCB1—nervous system—attention deficit hyperactivity disorder	9.94e-05	0.00161	CbGeAlD
Aripiprazole—ABCB1—central nervous system—attention deficit hyperactivity disorder	9.57e-05	0.00155	CbGeAlD
Aripiprazole—Perphenazine—DRD2—attention deficit hyperactivity disorder	9.52e-05	0.0156	CrCbGaD
Aripiprazole—ABCB1—cerebellum—attention deficit hyperactivity disorder	9.36e-05	0.00151	CbGeAlD
Aripiprazole—ABCB1—brain—attention deficit hyperactivity disorder	7.6e-05	0.00123	CbGeAlD
Aripiprazole—Perphenazine—HTR2A—attention deficit hyperactivity disorder	7.35e-05	0.0121	CrCbGaD
Aripiprazole—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.08e-06	3.81e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	6.07e-06	3.8e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.07e-06	3.8e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.06e-06	3.8e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.06e-06	3.79e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.05e-06	3.79e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.05e-06	3.79e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	6.01e-06	3.77e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.99e-06	3.75e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.98e-06	3.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.97e-06	3.74e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	5.97e-06	3.74e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.93e-06	3.72e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.92e-06	3.71e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.92e-06	3.71e-05	CbGpPWpGaD
Aripiprazole—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.9e-06	3.7e-05	CbGpPWpGaD
Aripiprazole—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.87e-06	3.68e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	5.86e-06	3.67e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.85e-06	3.67e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.84e-06	3.66e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.81e-06	3.64e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.8e-06	3.63e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.76e-06	3.61e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.75e-06	3.6e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.73e-06	3.59e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.71e-06	3.58e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.71e-06	3.58e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.68e-06	3.56e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.64e-06	3.53e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.64e-06	3.53e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.62e-06	3.52e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.6e-06	3.51e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.57e-06	3.49e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.57e-06	3.49e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.57e-06	3.49e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	5.56e-06	3.48e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.56e-06	3.48e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.55e-06	3.48e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.55e-06	3.48e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.55e-06	3.48e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.54e-06	3.47e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.52e-06	3.46e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.51e-06	3.45e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.49e-06	3.44e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.47e-06	3.43e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	5.47e-06	3.43e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.46e-06	3.42e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.44e-06	3.41e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.39e-06	3.38e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.39e-06	3.37e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.37e-06	3.36e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.37e-06	3.36e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.36e-06	3.36e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.34e-06	3.35e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.33e-06	3.34e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.29e-06	3.31e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.28e-06	3.31e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.25e-06	3.29e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.22e-06	3.27e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.18e-06	3.25e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.18e-06	3.25e-05	CbGpPWpGaD
Aripiprazole—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.18e-06	3.25e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.18e-06	3.24e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.16e-06	3.23e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.13e-06	3.22e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.13e-06	3.22e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	5.12e-06	3.21e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.1e-06	3.2e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.09e-06	3.19e-05	CbGpPWpGaD
Aripiprazole—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.09e-06	3.19e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.08e-06	3.19e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.07e-06	3.18e-05	CbGpPWpGaD
Aripiprazole—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.07e-06	3.18e-05	CbGpPWpGaD
Aripiprazole—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.05e-06	3.17e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.03e-06	3.15e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.02e-06	3.15e-05	CbGpPWpGaD
Aripiprazole—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5e-06	3.13e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5e-06	3.13e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.99e-06	3.13e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.99e-06	3.13e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.99e-06	3.13e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.97e-06	3.11e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.91e-06	3.08e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.91e-06	3.08e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.89e-06	3.06e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.87e-06	3.05e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.85e-06	3.04e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.85e-06	3.04e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.83e-06	3.03e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.83e-06	3.02e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.79e-06	3e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	4.79e-06	3e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.78e-06	3e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.77e-06	2.99e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.76e-06	2.98e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.75e-06	2.98e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.75e-06	2.98e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.72e-06	2.96e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.71e-06	2.95e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.7e-06	2.95e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.69e-06	2.94e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.69e-06	2.94e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.68e-06	2.93e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.68e-06	2.93e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	4.66e-06	2.92e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.64e-06	2.9e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	4.63e-06	2.9e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.62e-06	2.89e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.62e-06	2.89e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.6e-06	2.88e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.59e-06	2.87e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.54e-06	2.85e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.53e-06	2.84e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.53e-06	2.84e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	4.52e-06	2.83e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.52e-06	2.83e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.5e-06	2.82e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	4.49e-06	2.81e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.46e-06	2.79e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.45e-06	2.79e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.44e-06	2.78e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.43e-06	2.78e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.42e-06	2.77e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.39e-06	2.75e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.38e-06	2.74e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.37e-06	2.74e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.36e-06	2.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.36e-06	2.73e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.32e-06	2.7e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.31e-06	2.7e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.31e-06	2.7e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.3e-06	2.7e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.29e-06	2.69e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.28e-06	2.68e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.28e-06	2.68e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.27e-06	2.68e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.26e-06	2.67e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.24e-06	2.66e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.24e-06	2.66e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.24e-06	2.66e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.23e-06	2.65e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.23e-06	2.65e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.23e-06	2.65e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.22e-06	2.64e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.21e-06	2.64e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.21e-06	2.64e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.19e-06	2.63e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	4.19e-06	2.63e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.19e-06	2.63e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.18e-06	2.62e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.17e-06	2.61e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.17e-06	2.61e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.15e-06	2.6e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.15e-06	2.6e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.15e-06	2.6e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	4.13e-06	2.59e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.11e-06	2.58e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.1e-06	2.57e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.09e-06	2.56e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.05e-06	2.54e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.03e-06	2.53e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	4.01e-06	2.51e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	3.98e-06	2.49e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	3.95e-06	2.48e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.95e-06	2.48e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.93e-06	2.46e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.9e-06	2.45e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.9e-06	2.44e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.9e-06	2.44e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	3.89e-06	2.44e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	3.89e-06	2.44e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.88e-06	2.43e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.87e-06	2.42e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.86e-06	2.42e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.84e-06	2.4e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.83e-06	2.4e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.82e-06	2.39e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.81e-06	2.39e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.74e-06	2.35e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.68e-06	2.31e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	3.68e-06	2.3e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	3.65e-06	2.29e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.63e-06	2.27e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.62e-06	2.26e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.55e-06	2.22e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	3.37e-06	2.11e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.35e-06	2.1e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	3.34e-06	2.09e-05	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.32e-06	2.08e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.31e-06	2.07e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.28e-06	2.05e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.19e-06	2e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.16e-06	1.98e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.16e-06	1.98e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.15e-06	1.97e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.06e-06	1.92e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.01e-06	1.89e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.01e-06	1.88e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.93e-06	1.84e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.78e-06	1.74e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.73e-06	1.71e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.72e-06	1.7e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.71e-06	1.7e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.68e-06	1.68e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.68e-06	1.68e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	2.58e-06	1.62e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.58e-06	1.62e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	2.54e-06	1.59e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	2.54e-06	1.59e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	2.52e-06	1.58e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.49e-06	1.56e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	2.39e-06	1.5e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	2.38e-06	1.49e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.36e-06	1.48e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.27e-06	1.42e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.26e-06	1.42e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.25e-06	1.41e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.2e-06	1.38e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.17e-06	1.36e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.14e-06	1.34e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.07e-06	1.3e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.07e-06	1.29e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.05e-06	1.28e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	2e-06	1.25e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.97e-06	1.23e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.95e-06	1.22e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	1.94e-06	1.22e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.92e-06	1.21e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.75e-06	1.1e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.74e-06	1.09e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	1.72e-06	1.08e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.68e-06	1.05e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.67e-06	1.04e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.62e-06	1.02e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.6e-06	1e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	1.58e-06	9.87e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	1.57e-06	9.81e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	1.55e-06	9.74e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.47e-06	9.22e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.45e-06	9.07e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.45e-06	9.05e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	1.44e-06	9.05e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.44e-06	9.03e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.44e-06	9e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.42e-06	8.91e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.42e-06	8.89e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.32e-06	8.26e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	1.09e-06	6.83e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	1.03e-06	6.43e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	6.71e-07	4.21e-06	CbGpPWpGaD
